Sequential penile ultrasound monitoring of patients treated with chronic intracavernous prostaglandin E 1

By Hirsch I.H.   Schanne F.J.   Carsello J.   Bagley D.H.   Alexander A.A.  

Urology, Vol. 45, Iss. 6, 1995-06 ,pp. : 1037-1041

Elsevier

Access to resources Recommend Favorite

Liposome encapsulated prostaglandin E 1 in erectile dysfunction: correlation between in vitro delivery through foreskin and efficacy in patients - color Doppler flow sonography versus conventional techniques

By Foldvari M.   Oguejiofor C.   Afridi S.   Kudel T.   Wilson T.  

Urology, Vol. 52, Iss. 5, 1998-11 ,pp. : 838-843

Elsevier

Access to resources Recommend Favorite

Reasons for discontinuing intracavernous injection therapy with prostaglandin E 1 (alprostadil) - the sexual and psychological responses of women to their partner's treatment with self-injection or external vacuum therapy

By Lehmann K.   Casella R.   Blochlinger A.   Gasser T.C.  

Urology, Vol. 53, Iss. 2, 1999-02 ,pp. : 397-400

Elsevier

Access to resources Recommend Favorite

Methylene blue as a means of treatment for priapism caused by intracavernous injection to combat erectile dysfunction

By Hübler J.   Szántó Á.   Könyves K.  

International Urology and Nephrology, Vol. 35, Iss. 4, 2003-01 ,pp. : 519-521

Springer Publishing Company

Access to resources Recommend Favorite

Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra)

By Shabsigh R.   Padma-Nathan H.   Gittleman M.   McMurray J.   Kaufman J.   Goldstein I.  

Urology, Vol. 55, Iss. 4, 2000-04 ,pp. : 477-480

Elsevier

Access to resources Recommend Favorite